fda compounding semaglutide enforcement november 2025 news is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified FDA Crackdown on Compounded GLP-1
Description
Patients frequently report clearer thinking, steadier energy, and less brain fog, which can have a meaningful impact on quality of life as part of a broader longevity strategy
By month 4 or 5, most patients reach their therapeutic dose with minimal or no nausea, allowing them to focus on sustainable weight loss rather than side effect management
To maintain product stability and integrity
[2] Thats why its smart to keep an eye on your gut health
Despite an initial weight loss of approximately 50 kg, she ultimately regained most of her lost weight
Endocrinology 150 (3), 11741181
